Organisation paid for research Program year 2024 Source: CMS Open Payments

WR MCCR LCC

Neither a doctor nor a teaching hospital

Research payments

$5,558,872

416 payments

Through program year 2024, WR MCCR LCC is reported as receiving $5,558,872 in research payments, across 416 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$267,298	15
2023	Research	$2,392,058	314
2022	Research	$1,469,001	40
2021	Research	$1,403,596	42
2020	Research	$26,919	5

Breakdown

Who paid Research payments · program years 2020–2024

Moderna TX, Inc. $5,531,953 411 payments
GlaxoSmithKline, LLC. $26,919 5 payments

Studies the money was for Research payments · program years 2020–2024

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,804,931 54 payments
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $2,181,756 70 payments
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $273,938 21 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $206,624 255 payments
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. $45,115 7 payments
A Phase 3 Study to Compare the Efficacy and Safety of Gepotidacin With $26,919 5 payments
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age $19,589 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.